参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌临床疗效分析

An Analysis of Clinical Effects of ShenQi Tumor-inhibiting Prescriptions Jointed with Neoadjuvant Chemotherapy in Treating Cervical Carcinoma at Advanced Stage

目的:观察参芪抑瘤方联合新辅助化疗治疗中晚期宫颈癌的临床疗效。方法:将60例Ⅱb~Ⅲb期宫颈癌患者随机分为观察组、对照组各30例。2组均给予新辅助化疗方案,观察组同时服用参芪抑瘤方,治疗达到手术指征。观察2组患者肿瘤直径改善状况、肿瘤转移情况、治疗前后血清免疫学细胞前后变化、对化疗的耐受情况、副反应、3年生存率及临床疗效。结果:总有效率观察组为66.7%,对照组为40.0%,2组比较差异有统计学意义(P<0.05);化疗时间观察组短于对照组,2组比较差异有统计学意义(P<0.05)。肿瘤直径治疗后2组均明显缩小,与治疗前比较差异有统计学意义(P<0.05);治疗后组间比较差异也有统计学意义(P<0.05)。CD3^+、CD4^+、CD4^+/CD8^+、NK细胞治疗后观察组均显著升高,差异有统计学意义(P<0.05);治疗后观察组无明显变化(P>0.05);治疗后2组组间比较,差异有统计学意义(P<0.05)。3年生存率、局部复发率、远处转移率2组比较,差异有统计学意义(P<0.05)。化疗耐受率观察组为93.3%,对照组为83.3%,2组比较差异无统计学意义(P>0.05)。血小板减少情况及白细胞减少情况,2组比较差异无统计学意义(P>0.05)。结论:参芪抑瘤方有助于提高新辅助化疗疗效,减少化疗周期,提升患者免疫水平,提高治疗耐受性及依从性。

Objective： To survey clinical effects of ShenQi tumor-inhibiting prescriptions jointed with neoadju- vant chemotherapy in treating cervical carcinoma at advanced stage. Methods： Sixty patients were randomized into the observation group and the control group, 30 cases each group. Both groups were given with neoadjuvant chemotherapy, the observation group took ShenQi tumor-inhibiting prescription simultaneously, and the treatment reached the operation indications. Clinical effects, survival rate within three years, adverse reaction, the tolerance conditions of chemotherapy, and the changes of serum immune cells before and after treating, tumor metastasis, as well as the improvements of tumor diameters of both groups were observed. Results： Total effective rate of the observation group was 66.7%, higher than 40.0% of the control group, and the difference had statistical meaning （P〈0.05）; the observation group was shorter than the control group in the chemotherapy time, and the difference showed statistical meaning （P〈0.05）. Tumor diameters of both groups decreased obviously after treating, and the difference had statis- ileal meaning compared with before treating （P〈0.05）; the difference had statistical meaning between both groups after treating （P〈0.05）. The numbers of CD3＋, CD4＋, CD4＋/CD8＋ and NK cells of the observation group raised significantly after treating, and the difference had statistical meaning （P〈0.05）; there was no obvious changes in the observation group after treating （P〉0.05）; the difference had statistical meaning in the comparison between both groups after treating （P〈0.05）. The difference had statistical meaning in the comparisons of survival rate within three years, local relapse rate and distant metastasis rate between both groups （P〈0.05）. The tolerance rate of chemotherapy of the observation group was 93.3%, higher than 83.3% of the control group, and the difference had no statistical meaning between both groups （P〉0.05）. The difference had no statistical meaning in the comparisons of thrombopenia and aleukocytosis conditions （P〉 0.05）. Conclusion： She nQi tumor-inhibiting prescription is helpful to improve clinical effects of neoadjuvant chemotherapy, reduce chemotherapy cycle, and improve the immunity of the patients as well as therapeutic tolerance and compliances.